This article was originally published on this site
Qiagen N.V. (QGEN) traded on unusually high volume on Jul. 12, as the stock gained 1.08% to close at $37.35. On the day, Qiagen N.V. saw 1.5 million shares trade hands on 12,456 trades. Considering that the stock averages only a daily volume of 967,212 shares a day over the last month, this represents a pretty significant bump in volume over the norm.
Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.
The stock has traded between $37.61 and $30.20 over the last 52-weeks, its 50-day SMA is now $35.90, and its 200-day SMA $33.50. Qiagen N.V. has a P/B ratio of 3.29. It also has a P/E ratio of 152.6.
Qiagen NV provides sample and assay technologies to extract, purify, amplify, and interpret DNA (Deoxyribonucleic acid), RNA (Ribonucleic acid), and proteins. It also offers kits, assays, related automated systems and bioinformatics solutions.
Headquartered in Venlo, , Qiagen N.V. has 4,700 employees and is currently under the leadership of CEO Peer M. Schatz.
For a complete fundamental analysis analysis of Qiagen N.V., check out Equities.com’s Stock Valuation Analysis report for QGEN.
Still paying commissions on stock trades? Equities.com now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by https://www.equities.com/trading
To get more information on Qiagen N.V. and to follow the company’s latest updates, you can visit the company’s profile page here: QGEN’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer